Diseases & Conditions Market Research Reports & Industry Analysis
Insomnia is a common condition in which one has trouble going to sleep or staying asleep. This condition can range from weak to strong, depending on how often it occurs and for how long. Insomnia can be ongoing or acute. Chronic insomnia means having symptoms at least 3 nights a week for more than a month. Acute insomnia lasts for less time. Some people who have insomnia will have trouble falling asleep. Other people may fall asleep easily but, then wake up.
Diseases & Conditions Industry Research & Market Reports
-
Deep Brain Stimulation Devices
... 2030, growing at a CAGR of 8.5% over the analysis period 2024-2030. Dual-Channel, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$1.7 Billion by the end ... Read More
-
Pulmonary Arterial Hypertension (PAH)
... 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Prostacyclin & Prostacyclin Analogs, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$4.3 Billion ... Read More
-
Herpes Simplex Virus Infections
... 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR The Herpes Simplex Virus Infections market ... Read More
-
Huntington`s Disease Therapeutics
... at a CAGR of 31.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 40.0% CAGR The Huntington`s Disease Therapeutics market in the U.S. ... Read More
-
Alcoholic Hepatitis Treatment
... at a CAGR of 4.3% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$1.7 Billion by the end of the ... Read More
-
Wearable Fitness Technology
... at a CAGR of 13.3% over the analysis period 2024-2030. Smartwatches, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$11.0 Billion by the end of the ... Read More
-
Translucent Concrete
... CAGR of 41.3% over the analysis period 2024-2030. Concrete, one of the segments analyzed in the report, is expected to record a 42.2% CAGR and reach US$118.5 Million by the end of the analysis period. ... Read More
-
Tabletop Kitchen Products
... at a CAGR of 4.1% over the analysis period 2024-2030. Dinnerware, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$22.9 Billion by the end of the ... Read More
-
Smart Insulin Pens and Pumps
... Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Pumps, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.9 Billion by ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Particle Therapy
... CAGR of 8.8% over the analysis period 2024-2030. Proton Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Metabolic Disorder Therapeutics
... at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of the ... Read More
-
Medical Refrigerators
... CAGR of 7.0% over the analysis period 2024-2030. Blood Bank Refrigerator & Plasma Freezer, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.6 Billion by the ... Read More
-
Disposable Blood Pressure Cuffs
... 2030, growing at a CAGR of 13.1% over the analysis period 2024-2030. Physicians, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$325.2 Million by the end ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Blood Glucose Monitoring Systems
... 2030, growing at a CAGR of 10.0% over the analysis period 2024-2030. Self-Monitoring, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$21.4 Billion by the end ... Read More
-
Ambulatory Electronic Health Record (EHR)
... Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Cloud, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$6.9 Billion by ... Read More
-
Radiodermatitis
... 4.2% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$412.0 Million by the end of the analysis period. Growth in ... Read More
-
Autoimmune Disease Therapeutics
... at a CAGR of 3.8% over the analysis period 2024-2030. Anti-inflammatory, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$183.0 Billion by the end of the ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. Growth ... Read More
-
Calcium Channel Blockers
... at a CAGR of 6.1% over the analysis period 2024-2030. Dihydropyridine, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.1 Billion by the end of the ... Read More
-
Walnut
... 2.9% over the analysis period 2024-2030. Black Walnuts, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$570.1 Million by the end of the analysis period. Growth ... Read More
-
Sexually Transmitted Diseases (STDs) Drug
... Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. HPV, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$74.3 Billion by ... Read More
-
Psoriasis Treatment
... CAGR of 6.5% over the analysis period 2024-2030. Interleukin Inhibitors, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$11.8 Billion by the end of the analysis ... Read More
-
Datacenter Deployment Spending
... at a CAGR of 13.5% over the analysis period 2024-2030. Localized, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$106.9 Billion by the end of the ... Read More
Research Assistance
